284 related articles for article (PubMed ID: 34689339)
41. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
42. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
da Costa Gonçalves F; Demirci E; Zwiers A
Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
[TBL] [Abstract][Full Text] [Related]
43. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
[TBL] [Abstract][Full Text] [Related]
44. Use of real-world evidence in postmarketing medicines regulation in the European Union: a systematic assessment of European Medicines Agency referrals 2013-2017.
Brown JP; Wing K; Evans SJ; Bhaskaran K; Smeeth L; Douglas IJ
BMJ Open; 2019 Oct; 9(10):e028133. PubMed ID: 31662354
[TBL] [Abstract][Full Text] [Related]
45. Typical pitfalls in applications for marketing authorization of biotechnological products in Europe.
Schneider CK; Schäffner-Dallmann G
Nat Rev Drug Discov; 2008 Nov; 7(11):893-9. PubMed ID: 18974748
[TBL] [Abstract][Full Text] [Related]
46. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
47. What is the European Medicines Agency?
Bighelli I; Barbui C
Epidemiol Psychiatr Sci; 2012 Sep; 21(3):245-7. PubMed ID: 22793154
[TBL] [Abstract][Full Text] [Related]
48. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
[TBL] [Abstract][Full Text] [Related]
49. Real-World Evidence in the Real World: Beyond the FDA.
Krause JH; Saver RS
Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
[TBL] [Abstract][Full Text] [Related]
50. Real-world evidence use in assessments of cancer drugs by NICE.
Bullement A; Podkonjak T; Robinson MJ; Benson E; Selby R; Hatswell AJ; Shields GE
Int J Technol Assess Health Care; 2020 Jul; ():1-7. PubMed ID: 32646531
[TBL] [Abstract][Full Text] [Related]
51. Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma.
Petrakis I; Kontogiorgis C; Nena E; Athanasakis K; Gougoula V; Kotsianidis I; Constantinidis TC
Expert Rev Hematol; 2019 Dec; 12(12):1063-1075. PubMed ID: 31524011
[No Abstract] [Full Text] [Related]
52. How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer.
Saesen R; Kantidakis G; Marinus A; Lacombe D; Huys I
Front Pharmacol; 2022; 13():969778. PubMed ID: 36091761
[No Abstract] [Full Text] [Related]
53. Are women appropriately represented and assessed in clinical trials submitted for marketing authorization? A review of the database of the European Medicines Agency.
Müllner M; Vamvakas S; Rietschel M; van Zwieten-Boot BJ
Int J Clin Pharmacol Ther; 2007 Sep; 45(9):477-84. PubMed ID: 17907590
[TBL] [Abstract][Full Text] [Related]
54. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
Klonoff DC
J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182
[TBL] [Abstract][Full Text] [Related]
55. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.
Nishioka K; Makimura T; Ishiguro A; Nonaka T; Yamaguchi M; Uyama Y
Clin Pharmacol Ther; 2022 Jan; 111(1):35-43. PubMed ID: 34528701
[TBL] [Abstract][Full Text] [Related]
56. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
[TBL] [Abstract][Full Text] [Related]
57. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
Cook G; France G; Holte Ø; Lorenti G; Tainsh D
PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
[TBL] [Abstract][Full Text] [Related]
58. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
59. Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis.
Byrne D; Prendergast C; Fahey T; Moriarty F
BMJ Open; 2023 May; 13(5):e068981. PubMed ID: 37188475
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval.
Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Egberts TC; Blackburn S; Persson I; Leufkens HG
Drug Saf; 2009; 32(12):1175-87. PubMed ID: 19916584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
